Rapamycin and Interleukin-10 Treatment Induces T Regulatory Type 1 Cells That Mediate Antigen-Specific Transplantation Tolerance

Balb/c, C57BL/6, and C3H female mice were purchased from Charles River (Calco, Italy). All mice were kept under specific pathogen-free conditions. Glucose levels in the tail venous blood were quantified using the Glucometer Elite system (Bayer, Wuppertal, Germany) and were always measured in the morning. Diabetes was induced in Balb/c mice by intravenous injection of streptozotocin (Sigma, St. Louis, MO) at 170 mg/kg. A diagnosis of diabetes was made after two sequential glucose measurements >350 mg/dl. All animal care procedures were performed according to protocols approved by the Hospital San Raffaele Institutional Animal Care and Use Committee (IACUC #255).

After being cultured overnight at 37°C, hand-picked C57BL/6 pancreatic islets (or C3H islets, when indicated) were transplanted (300 islets/mouse) under the kidney capsule of recipient diabetic mice, as previously described (19).

The treatment of the transplanted Balb/c mice began the day after transplant. Rapamycin (Rapamune; Wyeth-Ayerst, Pearl River, NY) was diluted in peanut oil (Sigma) and administered once daily for 30 consecutive days at a dose of 1 mg/kg by gavage. Human recombinant IL-10, which cross-reacts with mouse (BD Biosciences, Mountain View, CA), was diluted in PBS and administered twice daily for 30 consecutive days at 0.05 μg/kg, i.p. FK506 (Prograf; Fujisawa) was diluted in saline solution and administered once daily for 30 consecutive days at 0.3 mg/kg, i.p. Anti–mouse IL-2Rα chain mAbs (clone 7D4; BD Biosciences) were diluted in saline solution and administered intraperitoneally at time 0 and 4 days after islet transplantation to reach a dose of 1 mg/mouse.

The Balb/c mice who did not reject the allograft 100 days after transplantation were boosted in vivo with allogeneic splenocytes. A total of 30 × 10⁶ splenocytes isolated from C57BL/6 mice were injected into those mice intraperitoneally, and the animals’ blood glucose levels were monitored daily thereafter.

Long-term tolerant Balb/c transplanted mice were treated with anti–IL-10R mAbs (clone 1B1.2; a kind gift of Dr. Kevin Moore) diluted in saline solution and administered intraperitoneally 140, 142, and 144 days after transplantation to reach a dose of 1 mg/mouse.

Ovalbumin peptide 323–339 (OVA; Primm, Milan, Italy) emulsified in complete Freund’s adjuvant (Difco, Detroit, MI) was injected once at 100 μg/mouse, s.c., in the hind footpads of transplanted Balb/c mice. Draining lymph nodes were collected and used in the in vitro assays.

Total RNA was extracted with Eurozol (Euroclone, Lugano, Switzerland), and cDNA was synthesized with a high-capacity cDNA archive kit (Applied Biosystems, Branchburg, NJ). Levels of FoxP3 mRNA were quantified using Assay on Demand real-time PCR kits (Applied Biosystems) with TaqMan Universal PCR Master Mix (Applied Biosystems). The levels of 18s rRNA were quantified as the internal control by using TaqMan PDAR eukaryotic 18s endogenous controls (Applied Biosystems; assay Mm00475156_m1). Samples were run in duplicate, and the relative expression of FoxP3 was determined by normalizing the expression in each set of samples to 18s to calculate a fold-change in value.

Spleen and lymph nodes were collected from untreated or treated mice. Total cells were incubated with microbeads coated with anti-CD4 mAbs and applied onto MiniMacs columns (Miltenyi Biotec, Bergisch Gladbach, Germany). Purified T-cells (2 × 10⁵/well) were cultured in 96-well plates precoated with anti-CD3 mAbs (10 μg/ml) in the presence of soluble anti-CD28 mAbs (1 μg/ml; BD Biosciences). As an alternative, total lymph nodes collected from mice immunized with OVA were cultured (4 × 10⁵ cells/well) in 96-well plates with 1 μmol/l OVA peptide. To measure cell proliferation, cultures were pulsed for the last 10 h of culture with 1 μCi of ³H-labeled thymidine. IL-10–producing cells were purified with a murine secretion assay enrichment and detection kit (Miltenyi Biotec).

For suppression experiments, naïve Balb/c CD4⁺ T-cells were stained with carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes), as described elsewhere (20), and cultured in 96-well plates (2 × 10⁵/well) in the presence of 10 μg/ml anti-CD3 mAbs. T-cell clones were added in a 1:1 ratio (i.e., 10⁵:10⁵) to the culture, and the percentage of divided naïve cells was evaluated and compared with the percentage of divided cells in the absence of any added cells.

The proportion of CFSE⁺ cells proliferating in vitro was calculated as described elsewhere (21). Briefly, the number of precursors in each cell division (n) was divided by 2 raised to power n. The sum of the original precursors from division one to six represents the number of precursors cells that proliferated. The percentage of CFSE⁺ divided cells was calculated as the number of precursors that proliferated (division 1–6) divided by the number of total precursors (division 0–6) × 100.

Lymphocytic infiltration of the transplanted islets was evaluated on hematoxylin-eosin–stained frozen sections of kidney taken at several levels throughout the organ.

Cells were stained with the indicated mAbs (all from BD Biosciences) and analyzed with a fluorescence-activated cell sorting (FACS) scan equipped with CellQuest software (BD Biosciences).

To measure the cytokines released in media, purified T-cells (1 × 10⁵/well) were cultured in 96-well plates and stimulated with 10 μg/ml immobilized anti-CD3 and 1 μg/ml soluble anti-CD28 mAbs (BD Biosciences). Supernatants were collected after 48 h for the detection of IL-2, -4, and -5 and γ-interferon and after 96 h for the detection of IL-10 and TGF-β of culture. Cytokines present in the collected supernatants were quantified by a sandwich enzyme-linked immunosorbent or a flow cytometry–based assay (cytokine beads assay) using standard commercially available kits (BD Biosciences). To measure cytokines present in the serum, peripheral blood collected from the tail vein of the transplanted animals was centrifuged and the serum frozen. The cytokines present in the collected sera were quantified by a flow cytometry–based assay (BD Biosciences).

Total splenocytes from long-term Balb/c tolerant mice were stimulated in vitro with irradiated C57BL/6 splenocytes (i.e., original donor). After 10 days of culture, CD4⁺ T-cells were magnetically purified and subsequently cloned at 1 cell/well in 96-well round-bottom plates in the presence of 10 μg/ml anti-CD3 and 1 μg/ml anti-CD28 mAbs (BD Biosciences). After 3 days of culture, 50 units/ml of IL-2 were added. At day 14, growing wells were picked and restimulated with irradiated C57BL/6 splenocytes, 1 μg/ml anti-CD3 mAbs, and 100 units/ml IL-2. Clones were split as necessary and restimulated as described above every 14 days. The medium was replenished every 3–5 days. Clones were used for experiments 10–14 days after restimulation.

Differences between groups were assessed using Student’s t test. P values were two tailed. Islet allograft survivals were determined using Kaplan-Meier survival curves and were compared by the log-rank test.

Diabetic Balb/c mice transplanted with pancreatic islets isolated from fully mismatched C57BL/6 mice were treated from day 1 to 30 with IL-10, which is the crucial cytokine for Tr1 cell differentiation (6). The efficacy of this treatment was compared with standard immunosuppression consisting of rapamycin plus FK506 plus anti–IL-2Rα chain mAbs (the Edmonton protocol) (18). The administration of IL-10 alone at doses demonstrated to be tolerogenic in the setting of bone marrow transplantation (22) was ineffective in preventing pancreatic islet graft rejection (Fig. 1A). IL-10 administered together with rapamycin led to graft survival in 75% of the mice, and rapamycin alone was effective in preventing graft rejection in 50% of the transplanted mice. Graft survival was observed in 77% of the mice treated with the Edmonton protocol (Fig. 1A). The Edmonton protocol was chosen as the comparison group because it is the most commonly used protocol in human islet transplantation. In addition, we wanted to define whether the test protocols were as effective as the Edmonton treatment in preventing graft rejection and whether they could promote tolerance with an appropriate contrasting protocol that provides data in the context of graft acceptance by immunosuppression.

To define whether antigen-specific tolerance rather than general immunosuppression was achieved in mice treated with rapamycin plus IL-10, we investigated whether the mice had the ability to respond to a given antigen in vivo. Transplanted mice were immunized with OVA at least 70 days after treatment withdrawal, and cells from the draining lymph nodes were collected 10 days after immunization. Cells from mice treated with the Edmonton protocol could not mount a proliferative response to OVA. In contrast, cells from mice treated with rapamycin plus IL-10 had a response similar to that of untransplanted immunized control mice (Fig. 1B). These data showed that standard immunosuppression induced a general state of unresponsiveness that persisted for >70 days after treatment withdrawal. This was not an unexpected finding, as it has been shown that T-cells isolated from bone marrow–transplanted patients treated with cyclosporine A can remain in a state of in vitro unresponsiveness for at least 6 months after treatment withdrawal (23). In contrast to the Edmonton protocol, rapamycin plus IL-10 treatment did not impair the long-term ability of T-cells to respond to a given antigen.

To determine whether the graft survival achieved in mice treated with the Edmonton protocol, rapamycin plus IL-10, or rapamycin alone was associated with an active state of tolerance, transplanted mice were rechallenged in vivo with splenocytes isolated from the original donor. After the injection of allogeneic splenocytes, 80% of the mice treated with the Edmonton protocol and 60% of the mice treated with rapamycin alone promptly rejected the graft. In contrast, only 17% of the mice treated with rapamycin plus IL-10 rejected the graft after in vivo rechallenge (Fig. 1C). These results, together with the profound state of immune incompetence observed 100 days after transplantation in the Edmonton-treated mice (Fig. 1B), indicated that no active tolerance was achieved with this therapy and that only the injection of donor-derived antigens could break the state of immune incompetence leading to graft rejection. On the contrary, rapamycin plus IL-10–treated mice displayed a state of active and stable long-term tolerance that could not be broken by alloantigen rechallenge. Overall, the proportion of mice achieving long-term tolerance (i.e., accepting the primary graft and retaining the graft after rechallenge) was 63% in mice treated with rapamycin plus IL-10, 20% in mice treated with rapamycin alone, and 15% in mice treated with the Edmonton protocol (Table 1).

The mechanisms by which rapamycin plus IL-10 treatment induces long-term tolerance were investigated in mice that did not reject the graft 100 days after transplantation. Untreated mice or mice treated with the Edmonton protocol were used as controls. The magnitude of cellular infiltration in the graft was comparable in all groups examined. However, infiltrating cells were confined to the periphery of the islets in mice treated with rapamycin plus IL-10 or the Edmonton protocol, whereas intra-islet infiltrating mononuclear cells were observed only in the control, untreated mice (Fig. 2).

It has been shown that rapamycin profoundly affects the phenotype and function of dendritic cells by reducing their antigen-uptake capacity, thereby favoring the differentiation of tolerogenic dendritic cells (24). In our experimental model, the percentage of dendritic cells, macrophages, and B-cells and the expression levels of the costimulatory molecules CD80 and CD86 on these cell subsets were comparable in the spleen and draining renal lymph nodes of control and treated mice (data not shown). These data indicated that 30 days of treatment with rapamycin plus IL-10 did not affect the number or phenotype of professional antigen-presenting cells. Moreover, the same proportion of CD8⁺ and CD4⁺ T-cells was observed in the spleen and lymph nodes of control and Edmonton- and rapamycin plus IL-10–treated mice (data not shown).

To determine whether CD4⁺CD25⁺ Tr cells play a role in the induction of long-term tolerance in rapamycin plus IL-10–treated mice, the percentage of CD4⁺CD25⁺ T-cells was analyzed by FACS. The frequency of CD4⁺CD25⁺ T-cells was similar in spleen and renal lymph nodes of control and Edmonton- and rapamycin plus IL-10–treated mice (Fig. 3A). Furthermore, FoxP3 expression, which strictly correlates with the presence of CD4⁺CD25⁺ Tr cells, was not increased in the spleen or renal lymph nodes of Edmonton- or rapamycin plus IL-10–treated mice (Fig. 3B).

A high proportion of Tr1-like cytokines (i.e., IL-10, IL-5, and TGF-β) was present in the spleens of tolerant mice treated with rapamycin plus IL-10 but not in the spleens of untreated mice or mice treated with the Edmonton protocol (Fig. 4A). Levels of Th1 cytokines (IL-2 and γ-interferon) and IL-4 were similar in untreated and Edmonton- and rapamycin plus IL-10–treated mice (Fig. 4A). IL-10–producing cells obtained from the spleen of Edmonton- and rapamycin plus IL-10–treated mice were enriched using the murine IL-10 secretion assay. A significant proportion of cells with a Tr1 cytokine phenotype (i.e., IL-10⁺IL-4⁻) was identified only in mice treated with rapamycin plus IL-10 (Fig. 4B). In addition, two Tr1 cell clones were isolated from the spleen of a rapamycin plus IL-10–treated mouse after donor alloantigen-specific stimulation but not from the spleen of Edmonton-treated mice. These T-cell clones were able to suppress in vitro cell proliferation of naïve syngeneic CD4⁺ T-cells after polyclonal stimulation, whereas a Th2 cell clone (IL-10⁺IL-4⁺) isolated from the same animal was not suppressive (Fig. 5).

These results demonstrated that IL-10 given in combination with rapamycin induces Tr1 cells in vivo. Rapamycin is not responsible for Tr1 cell induction, as CD4⁺ T-cells isolated from mice treated with rapamycin alone did not show any increase in IL-10 production (data not shown). IL-10–producing Tr1 cells were found in a reproducible manner in the spleen of all the animals treated with rapamycin plus IL-10, whereas the presence of Tr1 cells in the draining lymph nodes was not consistent (data not shown). These data suggest that Tr1 cells can be present at the site of the graft but are more frequently detected in the spleen.

To confirm that long-term tolerance was mediated by IL-10 produced by Tr1 cells, anti–IL-10R mAbs were given to long-term–tolerant mice treated with rapamycin plus IL-10. We observed that four of the five mice in which IL-10 activity was blocked in vivo promptly rejected the graft; one mouse was hyperglycemic after mAb treatment but never rejected the graft (Fig. 6A). In accordance with this experimental outcome, the mice that rejected the graft showed increased levels of inflammatory cytokines in their sera after anti–IL-10R mAb treatment: TNF-α levels increased from 12 to 50 pg/ml, IL-12 levels from 6 to 12 pg/ml, and IL-6 levels from 1 to 45 pg/ml (range of four animals). Overall these data indicate that long-term transplantation tolerance achieved with rapamycin plus IL-10 treatment is strictly dependent on the in vivo production of IL-10.

Adoptive transfer experiments in newly transplanted mice were performed to demonstrate that active tolerance induced by rapamycin plus IL-10 treatment can be transferred to a naïve mouse. Because a low number of IL-10–producing Tr1 cells could be isolated from rapamycin plus IL-10–treated mice, adoptive transfer experiments were performed with total CD4⁺ T-cells, which contain an average 10% of IL-10⁺IL-4⁻ Tr1 cells. The transfer of CD4⁺ splenic T-cells from long-term–tolerant mice treated with rapamycin plus IL-10 to secondary recipients completely prevented graft rejection of new transplants in the secondary recipients. In contrast, CD4⁺ T-cells isolated from untreated or Edmonton-treated mice were ineffective (Fig. 6B). This graft survival was due to antigen-specific tolerance, as was demonstrated when the adoptive transfer of CD4⁺ T-cells isolated from rapamycin plus IL-10–treated mice into secondary recipients that were transplanted with third-party alloantigens (i.e., islets from C3H mice) was ineffective in preventing rejection (Fig. 6C).

In this study, we demonstrated that a pharmacological approach that combines systemic administration of IL-10 with the immunosuppressive compound rapamycin prevents acute islet allograft rejection and induces Tr1 cells in vivo that mediate stable transplantation tolerance. These Tr1 cells secrete high levels of IL-10 and significant amounts of IL-5 and TGF-β. IL-10 is the cytokine that is crucial for the maintenance of long-term tolerance, as was shown when treatment with anti–IL-10R mAbs resulted in graft rejection. Tolerance is antigen specific, as demonstrated by the adoptive transfer experiments.

IL-10 is a well-characterized immunoregulatory cytokine with potent anti-inflammatory and suppressive activities. The central role of IL-10 in the induction of tolerance and maintenance of immunological homeostasis has been demonstrated in several experimental models (rev. in 25). However, systemic administration of recombinant IL-10 generated controversial results. In murine models of diabetes, the systemic administration of recombinant IL-10 or IL-10 expressed from recombinant adeno-associated virus (26,27) or plasmid (28) seems to protect against insulitis and islet destruction. In contrast, the local pancreatic production of IL-10 could either precipitate diabetes, as observed in transgenic animals (29,30), or fail to prevent the recurrence of diabetes in mice that receive islet transplants (31,32). Therefore, IL-10 has different effects in modulating autoimmune responses depending on dosage and site of administration. To reduce the variability related to the systemic administration of IL-10, the induction of regulated, endogenous IL-10 production might be advantageous. This goal can be achieved by the induction of Tr1 cells in vivo, which are long-living memory cells that produce IL-10 once they are activated (4).

In our experimental model, the mere administration of IL-10 during allogeneic islet transplantation was not effective in preventing rejection. To efficiently achieve transplantation tolerance via the induction of Tr cells, it is conceivable that one should simultaneously reduce inflammation, inhibit effector T-cell expansion while allowing T-cell activation, and induce/expand long-lasting antigen-specific Tr cells. It is likely that IL-10 induces the downregulation of inflammation and allows the induction of Tr1 cells, as previously demonstrated (25), but this might not be sufficient to block the expansion of T effector cells. To this purpose, an immunosuppressive compound with the ability to downmodulate the effector phase of the immune response should be administered together with IL-10.

Bacchetta et al. (7) showed that Tr1 cells specific for host alloantigens can be isolated from peripheral blood of severe combined immunodeficient patients in whom tolerance was achieved after HLA-mismatched hematopoietic stem cell transplantation. In these patients, the presence of donor-derived Tr1 cells correlated with high levels of IL-10 production and normal immune function in the absence of any immunosuppressive therapy. In contrast, in bone marrow transplant patients who received cyclosporine A and steroids as immunosuppressive treatment to control GvHD, Tr1 cells could not be isolated, although donor-derived T-cells specific for the host alloantigens were detectable (23). These study results clearly suggest that immunosuppressive drugs may interfere with the in vivo induction of Tr1 cells.

Compounds able to reduce the risk of graft rejection but also facilitate the development of antigen-specific Tr cells should allow T-cell activation, a prerequisite for Tr cell induction. Calcineurin inhibitors, such as cyclosporine A and FK506, by preventing T-cell activation might also prevent the generation of Tr cells (17). In contrast, rapamycin is an immunosuppressive drug that does not prevent T-cell activation but that does inhibit T-cell proliferation by blocking IL-2 signaling at a later stage after receptor engagement by binding to a cytosolic protein (FKBP-12) (33). The rapamycin–FKBP-12 complex binds to and blocks the mammalian target of rapamycin (mTOR), resulting in the inhibition of cytokine-induced T-cell proliferation. It has been shown that rapamycin-based therapies can be successful in inducing operational tolerance. The combined administration of rapamycin with agonist IL-2–and antagonist IL-15–related cytolytic fusion proteins has been shown to provide long-term engraftment/tolerance in exceptionally stringent allotransplant models (e.g., skin and islet allografts in NOD and IL-2 knockout mice) (34). Rapamycin and anti-CD40L–specific antibodies act synergistically to prolong skin allograft survival (35).

In our experimental model of allogeneic islet transplantation in chemically induced diabetic mice, rapamycin plus IL-10–treatment prevented graft rejection and induced Tr1 cells that were long lasting in the absence of any further treatment and mediated long-term tolerance in a fully immunocompetent host. Furthermore, this antigen-specific tolerance could be transferred into secondary recipients. This outcome was achieved only when rapamycin was given with IL-10, as Tr1 cells were not found in mice treated with rapamycin alone. In addition, treatment with rapamycin plus FK506 plus anti–IL-2Rα mAbs (the Edmonton protocol) led to a state of chronic immunosuppression without the induction of Tr1 cells and transplantation tolerance. This may have resulted from the use of the calcineurin inhibitor FK506, which blocks TCR-mediated activation and therefore may prevent the generation of Tr cells. These results are in line with data from clinical trials using the Edmonton protocol. This treatment was proven to be highly effective in preventing allogeneic pancreatic islet rejection in diabetic patients (18); however, chronic immunosuppressive therapy was required and the loss of graft function over time was reported in several patients (36).

In our experimental model, Tr1 cells induced by rapamycin plus IL-10 treatment preferentially resided in the spleen and only occasionally were found in the draining lymph nodes. This finding is in line with the observation by Chen et al. (37) that Tr1 cells reside in the spleen and suppress the migratory capacity of T effector cells in the target organ. On the other hand, it has been shown that Tr1 cells display a selective and enhanced capacity to migrate to inflamed tissues during an active immune response (38). It is possible that in our model, Tr1 cells resided preferentially in the graft early on after transplantation and that only subsequently, once a stable tolerance was reached, localized to the spleen.

In our model of allogeneic transplantation, tolerance induced by rapamycin plus IL-10 treatment was not dependent on the long-term induction/expansion of CD4⁺CD25⁺FoxP3⁺ Tr cells. Indeed, 30 days of treatment with rapamycin plus IL-10 did not result in an increase in CD4⁺CD25⁺FoxP3⁺ Tr cells in either spleen or draining lymph nodes of mice tested 100 days after transplantation. This was surprising, as we recently demonstrated that rapamycin expands a population of CD4⁺CD25⁺FoxP3⁺ Tr cells in vitro (39). Tian et al. (40) reported that although rapamycin per se can expand peripheral CD4⁺CD25⁺ T-cells in normal rats, the percentage of CD4⁺CD25⁺ cells returned to normal 30 days after rapamycin was withdrawn. Thus in our model, treatment with rapamycin might have had only a transient effect on the CD4⁺CD25⁺ Tr cells. On the other hand, it is possible that CD4⁺CD25⁺FoxP3⁺ Tr cells are not involved in maintaining long-term transplantation tolerance and that their key role is to respond to tissue damage to preserve homeostasis to self-antigens.

The adoptive transfer of purified splenic CD4⁺ T-cells from rapamycin plus IL-10–treated mice, but not those from Edmonton-treated mice, prevented allograft rejection in secondary recipients transplanted with islets from the same donor but not those from a third party. Although these experiments proved the presence of antigen-specific Tr cells only in the spleen of rapamycin plus IL-10–treated mice, the contribution of other CD4⁺ Tr cells different from Tr1 cells in adoptively transferring tolerance cannot be excluded.

The transplantation of islet allografts into spontaneously diabetic NOD mice provides an even more daunting challenge than the Balb/c allograft model because of the generalized defect in tolerance mechanisms and the presence of preactivated cytopathic islet-specific T-cells in NOD mice (41). Rabinovitch et al. (42) demonstrated that seven out of seven mice treated with rapamycin plus IL-2 were normoglycemic 25 days after syngeneic islet transplantation. However, the long-term efficacy of the above-mentioned regimen in NOD mice transplanted with allogeneic islets was not proved. Our preliminary data demonstrated that continuous treatment with rapamycin plus IL-10 starting the day after transplantation significantly delayed graft rejection in spontaneously diabetic NOD mice but did not induce long-term tolerance (data not shown). We have observed that to obtain long-term graft function in diabetic NOD mice, the combination of a depleting agent able to eliminate preactivated T-cells with rapamycin plus IL-10 is mandatory (M.B., unpublished observations).

Taken together, our results demonstrate that rapamycin is an immunosuppressive compound that can be administered with IL-10 to induce Tr1 cells in vivo. Simultaneous administration of an immunosuppressant (rapamycin) and a “Tr1 inducer” (IL-10) can at the same time eliminate/block the allogeneic T effector cells and induce/expand Tr1 cells. We have shown that the two events act synergistically to block graft rejection and induce transplantation tolerance in a nonstringent model of chemically induced diabetes. Interestingly, it has been demonstrated that Tr1 cells per se can inhibit diabetes development in NOD mice (37). This study strongly supports the hypothesis that the in vivo induction of Tr1 cells represents an attractive option for potential therapeutic intervention leading to long-term tolerance after allogeneic islet transplantation in autoimmune diabetes. The in vivo induction of Tr1 cells has several key advantages compared with ex vivo T-cell manipulation: the in vivo approach is safer and less cumbersome and allows for the induction of Tr1 cells specific for the antigen that causes the pathology. Therefore, the results from this study have important implications for the future therapeutic use of Tr cells in autoimmune diabetes.

This work was supported by the Italian Telethon Foundation and Juvenile Diabetes Research Foundation Grant JT-O1.

We thank Kevin Moore for the anti–IL-10R mAbs and Francesca Sanvito and Stefano Olivieri for the immunohistochemical analyses.